Anticancer Res

1. TAMBURO M, Buffettino E, Pepe P, Marletta G, et al
   Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
   Anticancer Res. 2024;44:2205-2210.
   

   >> Share

   
   

   
   BMC Cancer

2. IHEANACHO CO, Enechukwu OH
   Role of antihypertensive medicines in prostate cancer: a systematic review.
   BMC Cancer. 2024;24:542.
   

   >> Share

   
   
3. OBINATA D, Takayama K, Lawrence MG, Funakoshi D, et al
   Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
   BMC Cancer. 2024;24:554.
   

   >> Share

   
   
4. YANG L, Ruan Y, Xu H
   HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis.
   BMC Cancer. 2024;24:544.
   

   >> Share

   
   

   
   Br J Radiol

5. 
   Correction to: High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
   Br J Radiol. 2024 Apr 30:tqae083. doi: 10.1093.
   

   >> Share

   
   

   
   Clin Cancer Res

6. APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al
   A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
   Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
   

   >> Share

   
   

   
   Eur Radiol

7. MUGLIA VF
   Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.
   Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10734.
   

   >> Share

   
   

   
   Eur Urol

8. TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
   EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
   Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
9. OST P, Siva S, Zilli T
   OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
   Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
   

   >> Share

   
   
10. HU JC, Vickers AJ, Schaeffer EM
    Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
    Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
11. CHAKRABARTI D, Parker CC
    Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
    Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    J Clin Oncol

12. SAYAN M, Chen MH, Loffredo M, McMahon E, et al
    Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
    J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394.
    

    >> Share

    
    

    
    J Magn Reson Imaging

13. ABRAHAMSEN BS, Tandstad T, Aksnessaether BY, Bogsrud TV, et al
    Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management.
    J Magn Reson Imaging. 2024 Apr 28. doi: 10.1002/jmri.29386.
    

    >> Share

    
    

    
    J Nucl Med

14. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
    Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
    J Nucl Med. 2024;65:735-739.
    

    >> Share

    
    
15. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.
    

    >> Share

    
    

    
    J Urol

16. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    

    >> Share

    
    

    
    JAMA

17. CORNU JN
    Outcomes Following Localized Prostate Cancer Treatment.
    JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5489.
    

    >> Share

    
    
18. HUANG TB, Ding XF
    Outcomes Following Localized Prostate Cancer Treatment.
    JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5486.
    

    >> Share

    
    
19. BAROCAS DA, Al Hussein Al Awamlh B, Koyama T
    Outcomes Following Localized Prostate Cancer Treatment-Reply.
    JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5492.
    

    >> Share

    
    
20. HARRIS E
    Prostate Cancer Cases Might Rise to 3 Million Globally by 2040.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6729.
    

    >> Share

    
    

    
    Magn Reson Med

21. GUNDOGDU B, Medved M, Chatterjee A, Engelmann R, et al
    Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI.
    Magn Reson Med. 2024;92:319-331.
    

    >> Share

    
    

    
    Nat Rev Urol

22. NI X, Wei Y, Li X, Pan J, et al
    From biology to the clinic - exploring liver metastasis in prostate cancer.
    Nat Rev Urol. 2024 Apr 26. doi: 10.1038/s41585-024-00875.
    

    >> Share

    
    

    
    PLoS One

23. RAJANALA SH, Ghale R, Nandakumar S, Chadalavada K, et al
    Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting.
    PLoS One. 2024;19:e0301989.
    

    >> Share

    
    

    
    Prostate

24. MIYAHIRA AK, Kamran SC, Jamaspishvili T, Marshall CH, et al
    Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24721.
    

    >> Share

    
    
25. KARSH L, Du S, He J, Waters D, et al
    Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24720.
    

    >> Share

    
    

    
    Urology

26. VAN DER EECKEN H, Vansevenant B, Devos G, Roussel E, et al
    Nutritional supplement with fermented soy in men with an elevated risk of prostate cancer and negative prostate biopsies: General and oncological results from the prospective PRAECAP trial.
    Urology. 2024 Apr 24:S0090-4295(24)00300-5. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    
27. BOLOGNA E, Licari LC, Franco A, Ditonno F, et al
    Incidence and Management of Radiation Cystitis After Pelvic Radiotherapy for Prostate Cancer: Analysis from a National Database.
    Urology. 2024 Apr 29:S0090-4295(24)00308-X. doi: 10.1016/j.urology.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share